DWS ESG Biotech LC
DE0009769976
DWS ESG Biotech LC/ DE0009769976 /
NAV10/05/2024 |
Var.-4.7900 |
Type of yield |
Focus sugli investimenti |
Società d'investimento |
280.5500EUR |
-1.68% |
reinvestment |
Equity
Worldwide
|
DWS Investment GmbH ▶ |
Investment strategy
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund"s sustainable investment strategy.
Investment goal
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
Dati master
Type of yield: |
reinvestment |
Fondi Categoria: |
Equity |
Region: |
Worldwide |
Settore: |
Sector Biotechnology |
Benchmark: |
- |
Business year start: |
01/10 |
Ultima distribuzione: |
02/01/2018 |
Banca depositaria: |
State Street Bank International GmbH |
Domicilio del fondo: |
Germany |
Permesso di distribuzione: |
Austria, Germany |
Gestore del fondo: |
Dr. Noushin Irani |
Volume del fondo: |
364.61 mill.
EUR
|
Data di lancio: |
16/08/1999 |
Investment focus: |
- |
Condizioni
Sovrapprezzo emissione: |
5.00% |
Tassa amministrativa massima: |
1.30% |
Investimento minimo: |
0.00 EUR |
Deposit fees: |
- |
Redemption charge: |
0.00% |
Prospetto semplificato: |
Download (Print version) |
Società d'investimento
Funds company: |
DWS Investment GmbH |
Indirizzo: |
Mainzer Landstraße 11-17, 60329, Frankfurt am Main |
Paese: |
Germany |
Internet: |
www.dws.de
|
Attività
Stocks |
|
93.90% |
Money Market |
|
3.10% |
Cash |
|
3.00% |
Paesi
United States of America |
|
82.10% |
Netherlands |
|
4.10% |
Denmark |
|
3.20% |
Germany |
|
1.80% |
United Kingdom |
|
0.70% |
Ireland |
|
0.60% |
Virgin Islands (British) |
|
0.50% |
Canada |
|
0.40% |
Sweden |
|
0.30% |
Switzerland |
|
0.20% |
Altri |
|
6.10% |
Filiali
Pharma/Biotechnology |
|
89.70% |
Pharma, production |
|
4.30% |
Altri |
|
6.00% |